TCRR

TCR2 Therapeutics Inc. (TCRR) | Rumor.io

TCR2 Therapeutics

TCRR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about TCRR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Jun 1

TCR2 Therapeutics Inc. (TCRR) has filed several SEC forms, including Form 8-K, Form 4, and Form S-8, indicating recent corporate activity.
The company's stock has been halted by NASDAQ due to additional information requested, with a halt time of May 31, 2023.
Several company insiders, including directors and officers, have made transactions involving derivative securities and common stock, as reported in SEC Form 4 filings.

Generated by AI

Sentiment

Of the messages about TCRR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100%
Bearish	—	—	—	0%

Bullish· Mar 6

TCR2 Therapeutics Inc. (TCRR) has been issued a takeover, which could be a catalyst for growth.
The company's merger is paying $2.66 per share, implying that the stock is undervalued at its current price.
Breaking above $1.82 could be a key level for TCRR to reach new highs, according to some market analysts.

Bearish· Sep 17

The market is judging TCR2 Therapeutics' ($TCRR) data as bad, questioning the selection of abstracts for the ESMO press program.
Wedbush downgraded $TCRR to Neutral with a PT of $11.00, citing potholes ahead for the company.
$TCRR has reached a 15-month low, with the stock price declining -31.4% and hitting a new 52-week low, amid concerns over safety signals from the Gavo-cel solid tumor trial.

Generated by AI

Topics

Of the messages about TCRR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Analysts· Sep 20

Truist Securities maintained a Buy rating for TCR2 Therapeutics with a lower price target of $29.
Wedbush downgraded TCR2 Therapeutics to Neutral from Outperform with a lower price target of $11.
HC Wainwright and Wedbush analysts lowered their price targets for TCR2 Therapeutics to $25 and $11, respectively, while maintaining a Buy rating.

Announcements· Mar 23

TCR2 Therapeutics Inc. ($TCRR) released its Q4 2022 financial results and corporate updates, highlighting its agreement with Adaptimmune to merge into a preeminent cell therapy company focused on treating solid tumors.
The company reported its fourth-quarter and full-year 2022 financial results, providing a corporate update and highlighting its progress in the development of its cell therapy products.
TCR2 Therapeutics filed its Form 10-K with the SEC on March 23, 2023, providing detailed financial information and corporate updates for the quarter and year.

Generated by AI

Community

Of the messages about TCRR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	0%
Newcomers	—	—	100%	100%

Also Discussed

Investors talking about TCRR also mention

#	Name	Attention
1	Immunocore Holdings plc ADRIMCR	0%0
2	HARP - Harpoon Therapeutics, Inc.	——
3	ACHL - Achilles Therapeutics plc	——
4	WHLM - Wilhelmina International, Inc.	——
5	Immatics N.V.IMTX	0%0
6	Alector Inc.ALEC	0%new
7	Black Diamond Therapeutics, Inc.BDTX	0%new
8	Instil Bio Inc.TIL	0%0
9	Caribou Biosciences, Inc.CRBU	0%0
10	Precision BioSciences, Inc.DTIL	0%new